Taniborbactam (VNRX-5133)

Description: Taniborbactam (VNRX5133) is a novel, Phase 3-ready, reversible, selective, and injectable ß-lactamase inhibitor (BLI) that features uniquely potent and selective activity against both serine- and metallo-beta-lactamases. VNRX-5133 is under investigation in a fixed combination with the fourth generation cephalosporin, cefepime. Cefepime/VNRX-5133 may have the potential to provide a best-in-class broad-spectrum treatment option for infections due to carbapenem resistant pathogens including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA), bioterror pathogens such as Burkholderia spp. and Salmonella spp. engineerable with serine- and metallo-beta-lactamases, and suspected polymicrobial infections caused by both gram-negative and gram-positive pathogens.

References:

1. KrajncA, et al. Bicyclic Boronate VNRX-5133 Inhibits Metallo- andSerine-beta-Lactamases. J Med Chem. 2019 Sep 26; 62(18):8544-8556.

2. LiuB , et al. Discovery of Taniborbactam (VNRX-5133): A Broad-SpectrumSerine- and Metallo-beta-lactamase Inhibitor for Carbapenem-ResistantBacterial Infections. J Med Chem. 2019 Dec 16.

3. www.clinicaltrials.gov